NCT01590628View on ClinicalTrials.gov

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2018

Study Completion Date

October 31, 2019

Conditions
Sickle Cell Disease & Thalassemia
Interventions
DRUG

NiCord

NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells

Trial Locations (3)

11040

Steven & Alexandra Cohen Children's Medical Center, New York, New York

27705

Duke University Medical Center, Durham

77030-4009

The University Of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Gamida Cell ltd
All Listed Sponsors
lead

Gamida Cell ltd

INDUSTRY